1-2 of 2
Peter Folger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro

Hongying Zhang, Andrea Local, Khalid Benbatoul, Peter Folger, Susan Sheng, Cheng-Yu Tsai, Stephen B. Howell, William G. Rice
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 794.
DOI: https://doi.org/10.1158/1538-7445.AM2018-794
Published: 01 July 2018
View article
Journal Articles

Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors

Joseph Tumang, Bruno Gomes, Martin Wythes, Stefano Crosignani, Patrick Bingham, Pauline Bottemanne, Hélène Cannelle, Sandra Cauwenberghs, Jenny Chaplin, Deepak Dalvie, Sofie Denies, Coraline De Maeseneire, Peter Folger, Kim Frederix, Jie Guo, James Hardwick, Ken Hook, Katti Jessen, Erick Kindt, Marie-Claire Letellier, Kai-Hsin Liao, Wenlin Li, Karen Maegley, Reece Marillier, Nichol Miller, Brion Murray, Romain Pirson, Julie Preillon, Virginie Rabolli, Chad Ray, Stephanie Scales, Jay Srirangam, Jim Solowiej, Nicole Streiner, Vince Torti, Konstantinos Tsaparikos, Paolo Vicini, Gregory Driessens, Manfred Kraus
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4863.
DOI: https://doi.org/10.1158/1538-7445.AM2016-4863
Published: 15 July 2016
View article